Increased IFN-? synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia

References

• Molldrem JJ, Lee PP, Wang C et al, Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 6: 1018–23.
   Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al, Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients [European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia]. Blood (1995) 86: 20418–50.
   Google Scholar
• Goto S, Sato M, Kaneko R et al, Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother (1999) 48: 435–42.
   Google Scholar
• Reuben JM, Lee BN, Johnson H et al, Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin Cancer Res (2000) 6: 1671–7.
   Google Scholar
• Aswald JM, Lipton JH, Messner HA, Intracellular cytokine analysis of interferon-γ in T cells of patients with chronic myeloid leukemia. Cytokines Cell Mol Ther (2002) 7: 75–82.
   Google Scholar
• Elsasser-Beile U, von Kleist S, Stahle W et al, Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer (1993) 71: 231–6.
   Google Scholar
• Pellegrini P, Berghella AM, Del Beato T et al, Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother (1996) 42: 1–8.
   Google Scholar
• Ito N, Nakamura H, Tanaka Y, Ohgi S, Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer (1999) 85: 235–67.
   Google Scholar
• Druker BJ, Lydon NB, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 105: 3–7.
   Google Scholar
• O’Brien SG, Guilhot F, Larson RA et al, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 348: 994–1004.
   Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 344: 1031–7.
   Google Scholar
• Lucey DR, Clerici M, Shearer GM, Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 9: 532–62.
   Google Scholar
• Collins D, Multi-system approach to analysis of T-lymphocyte activation by flow cytometry: Utilization of intracellular cytokine expression, cytokine receptor expression, and quantification of cytokine secretion as an indicator of activation. Clin Immunol (1998) 18: 140–5.
   Google Scholar
• Filella X, Alcover J, Zarco MA et al, Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate (2000) 44: 271–4.
   Google Scholar
• Prussin C, Metcalfe DD, Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods (1995) 188: 117–28.
   Google Scholar
• Cho EK, Heo DS, Seol JG et al, Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br J Haematol (2000) 111: 216–22.
   Google Scholar
• Asanuma H, Sharp M, Maecker HT et al, Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 181: 859–66.
   Google Scholar
• Mincheff M, Altankova I, Zoubak S et al, In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-γ lymphokine profile. Crit Rev Oncol Hematol (2001) 39: 125–32.
   Google Scholar
• Rowley JD, Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243: 290–3.
   Google Scholar
• Hochhaus A, Reiter A, Skladny H et al, Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy. Recent Results Cancer Res (1998) 144: 36–45.
   Google Scholar
• Jung T, Schauer U, Heusser C et al, Detection of intracellular cytokines by flow cytometry. J Immunol Methods (1993) 159: 197–207.
   Google Scholar
• Chalmers IM, Janossy G, Contreras M, Navarrete C, Intracellular cytokine profile of cord and adult blood lymphocytes. Blood (1998) 92: 11–8.
   Google Scholar
• North ME, Ivory K, Funauchi M et al, Intracellular cytokine production by human CD4+ and CD8+ T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry. Clin Exp Immunol (1996) 105: 517–22.
   Google Scholar
• Daley GQ, Van Etten RA, Baltimore D, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247: 824–30.
   Google Scholar
• Druker BJ, Chronic myeloid leukemia. Sceptical scientists. Lancet (2001) 358: 11.
   Google Scholar
• Kiss TL, Abdolell M, Jamal N et al, Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol (2002) 20: 2334–43.
   Google Scholar
• Messner HA, Bone marrow transplantation in hemopoietic malignancies. Curr Opin Oncol (1991) 3: 245–53.
   Google Scholar
• Jiang YZ, Mavroudis D, Dermime S et al, Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol (1996) 93: 606–12.
   Google Scholar
• Romagnani S, Del Prete GF, Maggi E et al, Displacement of T lymphocytes with the ‘Helper/Inducer’ phenotype from peripheral blood to lymphoid organs in untreated patients with Hodgkin’s disease. Scand J Haematol (1983) 31: 305–14.
   Google Scholar
• Golub SH, Rangel DM, Morton DL, In vitro assessment of immunocompetence in patients with malignant melanoma. Int J Cancer (1977) 20: 873–80.
   Google Scholar
• Vose BM, Gallagher P, Moore M, Schofield PF, Specific and nonspecific lymphocyte cytotoxicity in colon carcinoma. Br J Cancer (1981) 44: 846–55.
   Google Scholar
• Sato M, Goto S, Kaneko R et al, Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res (1998) 18: 3951–5.
   Google Scholar
• Haanen JB, de Waal Malefijt R, Res PC et al, Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med (1991) 174: 583–92.
   Google Scholar
• Sher A, Coffman RL, Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol (1992) 10: 385–409.
   Google Scholar
• Yamamura M, Wang XH, Ohmen JD et al, Cytokine patterns of immunologically mediated tissue damage. J Immunol (1992) 149: 1470–5.
   Google Scholar
• Neurath AR, Strick N, Sproul P, Search for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope protein. J Exp Med (1992) 175: 461–9.
   Google Scholar
• Pawelec G, Rehbein A, Schlotz E, da Silva P, Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother (1996) 42: 193–9.
   Google Scholar
• Pawelec G, Schlotz E, Rehbein A, IFN-a regulates IL 10 production by CML cells in vitro. Cancer Immunol Immunother (1999) 48: 430–4.
   Google Scholar
• Denizot Y, Turlure P, Bordessoule D et al, Serum IL-10 and IL-13 concentrations in patients with haematological malignancies. Cytokine (1999) 11: 634–5.
   Google Scholar
• Norbury LC, Clark RE, Christmas SE, b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol (2000) 109: 616–21.
   Google Scholar
• Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH, Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med (1992) 176: 1283–9.
   Google Scholar
• Salomo M, Steinmann J, Glass B et al, Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assay. Bone Marrow Transplant (1995) 15: 179–86.
   Google Scholar
• Bertazzoli C, Marchesi E, Passoni L et al, Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res (2000) 6: 1931–5.
   Google Scholar
• Matar P, Rozados VR, Gervasoni SI, Scharovsky GO, Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother (2002) 50: 588.
   Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H et al, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 344: 1038–42.
   Google Scholar
• Gambacorti-Passerini C, Barni R, Marchesi E et al, Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol (2001) 112: 972–4.
   Google Scholar
• Druker BJ, Tamura S, Buchdunger E et al, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2: 561–6.
   Google Scholar
• Deininger MW, Goldman JM, Lydon N, Melo JV, The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood (1997) 90: 3691–8.
   Google Scholar
• Gambacorti-Passerini C, le Coutre P, Mologni L et al, Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis (1997) 23: 380–94.
   Google Scholar
• Nimmanapalli R, Porosnicu M, Nguyen D et al, Co-treatment with STI-571 enhances tumor necrosis factor a-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res (2001) 7: 350–7.
   Google Scholar
• Albert ML, Sauter B, Bhardwaj N, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392: 86–9.
   Google Scholar